A Phase 3 interventional study of Leuprorelin and Bicalutamide in Prostate Cancer, sponsored by Takeda. Completed at 2 sites in France. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-06-28.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 27th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2013, is one of 26 in phase 3, and was the 33rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Ontario Clinical Oncology Group (OCOG) · Sites in Canada
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 50 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 27 · Phase 4 9
First in 1994; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 77 across the 69 interventional studies. Of the 47 that completed or were terminated, 26 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 70 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
22 studies in Prostatic Neoplasms by Takeda: none open now, none under way, none of them phase 3. Of 22 finished, 13 (59%) have results posted.
Among the 22 studies in Prostatic Neoplasms by Takeda, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 3, and was the 16th registered.
Takeda’s Prostatic Neoplasms studies by the year they started, since 1996.
7 of the studies testing leuprolide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05169112Phase 3Ottawa Hospital Research InstituteImpact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | 2026-11 |
| NCT04302454Phase 3University Medical Center GroningenAndrogen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy | 2027-10-21 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT04249154McGill University Health Centre/Research Institute of the McGill University Health CentrePostop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer | 2026-12-15 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, from their registry updates:
Among Takeda’s 22 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess two treatment strategies (leuprorelin treatment and active surveillance without androgen deprivation) for indolent prostate cancer and to compare their therapeutic benefit for management of patients with low-risk, localized prostate cancer.
The drug being tested in this study is called leuprorelin. Leuprorelin is being tested to treat people who have prostate cancer. Study assessments will include adverse events, prostatic-specific antigen (PSA) levels, and prostate biopsies.
The study will enroll approximately 120 patients. Participants will be randomly assigned (by chance, like flipping a coin) to a treatment group that will receive leuprorelin 11.25 mg (as one injection) or to an untreated observation group. Patients in the leuprorelin group will also receive bicalutamide 50 mg, a non-steroidal antiandrogen, once daily for 15 days to prevent a flare-up.
This multi-center trial will be conducted in France. The overall time to participate in this study is 12 months. After the screening visit, participants will make 6 visits to the clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has indolent prostate cancer defined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
Drug: Leuprorelin · Drug: Bicalutamide
Active surveillance is close medical monitoring of prostate cancer for any changes.
Solution for injection
Also known as: Enantone ®
Bicalutamide tablets
Also known as: Casodex ®
Number of Participants With Negative Biopsies at Month 12
Staging biopsy of at least 12 cores were sampled and analyzed according to a centralized biopsy procedure which confirm the results of the first biopsy \[presence of positive cores, the absence of core with tumor length \> 3 millimeters (mm), and absence Grade 4 cells (Gleason score \< 7)\]. The Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.
Time frame: Month 12
Number of Participants With Gleason Score ≥ 7
Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.
Time frame: Month 12
Change From Baseline in the International Prostate Symptom Score (I-PSS) Total Symptom (S) Score
The I-PSS is an 8-question tool used to measure prostate symptoms (≤7: mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic). The first 7 symptom questions answered on a scale of 0 (never) to 5 (almost always) are used to determine the I-PSS Total S Score for a total possible score of 0 to 35. The 8th question is quality of life and is not reported here. A negative change from baseline indicates improvement. An Analysis of Covariance (ANCOVA) model fitted with baseline I-PSS total score and age as covariates was used for analysis.
Time frame: Baseline and Months 3, 6, 9 and 12
Prostatic Volume as a Measure of Tumor Radiologic Progression Using Dynamic Magnetic Resonance Imaging (MRI)
MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to calculate the prostatic volume in cubic millimeters (mm\^3).
Time frame: Baseline and Month 12
Highest Diameter of the Lesion as a Measure of Tumor Radiologic Progression Using Dynamic MRI
MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to determine the diameter of the lesions in millimeters (mm).
Time frame: Baseline and Month 12
Change From Baseline in Prostate-specific Antigen (PSA) Levels
Blood was collected and sent to a central laboratory for analysis of PSA reported in milligrams/milliliter (mg/mL). A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline PSA Level and age as covariates was used for analyses.
Time frame: Baseline and Months 3, 6, 9 and 12
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score
The HADS is a 14-item scale that measures anxiety (7-items) and depression (7-items) over the previous week. Each question is answered on a scale of 0 (best) to 3 (worst) for a total possible score of 0 to 42, with higher scores indicating more anxiety and depression. A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline HADS score and age as covariates was used for analyses.
Time frame: Baseline and Months 3, 6, 9 and 12
Change From Baseline in the International Index of Erectile Function (IIEF-5) Questionnaire Score
The IIEF-5, a 5 question patient completed questionnaire, is a measure of erectile dysfunction over the past 6 months. Each question is answered on a scale of 1 (worst) to 5 (best). Total score ranges from 5 to 25 with higher scores indicating better function (5-7: severe; 8-11: moderate; 12-16: mild to moderate;17-21: mild; 22-25: none). A positive change from baseline indicates improvement. A negative change from baseline indicates a worsening. An ANCOVA model fitted with baseline IIEF-5 score and age as covariates was used for analyses.
Time frame: Baseline and Months 3, 6, 9 and 12
Participants took part in the study at 22 investigative sites in France from 03 June 2013 to 08 November 2016.
| Milestone | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Started | 58 | 57 |
| Completed | 57 | 53 |
| Not completed | 1 | 4 |
| Withdrew: Withdrawal of consent | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Discontinuation due to patient decision | 0 | 1 |
| Withdrew: Reason not specified | 0 | 1 |
| Withdrew: Reason unknown | 0 | 1 |
Staging biopsy of at least 12 cores were sampled and analyzed according to a centralized biopsy procedure which confirm the results of the first biopsy \[presence of positive cores, the absence of core with tumor length \> 3 millimeters (mm), and absence Grade 4 cells (Gleason score \< 7)\]. The Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.
| Participants | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Number of Participants With Negative Biopsies at Month 12 | 28 | 17 |
Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.
| Participants | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Number of Participants With Gleason Score ≥ 7 | 1 | 3 |
The I-PSS is an 8-question tool used to measure prostate symptoms (≤7: mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic). The first 7 symptom questions answered on a scale of 0 (never) to 5 (almost always) are used to determine the I-PSS Total S Score for a total possible score of 0 to 35. The 8th question is quality of life and is not reported here. A negative change from baseline indicates improvement. An Analysis of Covariance (ANCOVA) model fitted with baseline I-PSS total score and age as covariates was used for analysis.
| score on a scale | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Change at Month 3 | 0.37 (-0.70 to 1.43) | 1.03 (-0.05 to 2.11) |
| Change at Month 6 | -0.38 (-1.27 to 0.51) | 0.32 (-0.59 to 1.24) |
| Change at Month 9 | -1.13 (-1.97 to -0.28) | 0.64 (-0.23 to 1.52) |
| Change at Month 12 | -0.48 (-1.52 to 0.56) | 0.93 (-0.14 to 2.01) |
MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to calculate the prostatic volume in cubic millimeters (mm\^3).
| mm^3 | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Baseline | 48.48 ± 25.09 | 49.44 ± 25.88 |
| Month 12 | 51.47 ± 28.15 | 48.33 ± 20.18 |
MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to determine the diameter of the lesions in millimeters (mm).
| mm | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Baseline | 6.39 ± 2.80 | 7.78 ± 2.02 |
| Month 12 | 6.25 ± 3.62 | 7.69 ± 2.56 |
Blood was collected and sent to a central laboratory for analysis of PSA reported in milligrams/milliliter (mg/mL). A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline PSA Level and age as covariates was used for analyses.
| mg/mL | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Change at Month 3 | -4.61 (-5.07 to -4.15) | 0.22 (-0.25 to 0.70) |
| Change at Month 6 | -3.27 (-3.95 to -2.59) | 0.85 (0.15 to 1.55) |
| Change at Month 9 | -1.46 (-1.96 to -0.95) | 0.71 (0.20 to 1.21) |
| Change at Month 12 | 0.17 (-0.69 to 1.04) | 0.76 (-0.13 to 1.66) |
The HADS is a 14-item scale that measures anxiety (7-items) and depression (7-items) over the previous week. Each question is answered on a scale of 0 (best) to 3 (worst) for a total possible score of 0 to 42, with higher scores indicating more anxiety and depression. A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline HADS score and age as covariates was used for analyses.
| score on a scale | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Change at Month 3 | -0.83 (-1.76 to 0.11) | -1.20 (-2.17 to -0.24) |
| Change at Month 6 | -1.44 (-2.53 to -0.35) | -1.58 (-2.69 to -0.47) |
| Change at Month 9 | -2.06 (-3.21 to -0.91) | -1.76 (-2.95 to -0.56) |
| Change at Month 12 | -1.87 (-2.98 to -0.76) | -1.95 (-3.09 to -0.80) |
The IIEF-5, a 5 question patient completed questionnaire, is a measure of erectile dysfunction over the past 6 months. Each question is answered on a scale of 1 (worst) to 5 (best). Total score ranges from 5 to 25 with higher scores indicating better function (5-7: severe; 8-11: moderate; 12-16: mild to moderate;17-21: mild; 22-25: none). A positive change from baseline indicates improvement. A negative change from baseline indicates a worsening. An ANCOVA model fitted with baseline IIEF-5 score and age as covariates was used for analyses.
| score on a scale | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Change at Month 3 | -7.40 (-9.02 to -5.78) | 0.00 (-1.65 to 1.65) |
| Change at Month 6 | -5.87 (-7.52 to -4.22) | 0.01 (-1.69 to 1.71) |
| Change at Month 9 | -1.94 (-3.20 to -0.67) | -0.38 (-1.69 to 0.94) |
| Change at Month 12 | -1.68 (-3.11 to -0.24) | -0.02 (-1.49 to 1.46) |
Collected over First dose of study drug to the End of Study Visit (Up to 12 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprorelin 11.25 mg | — | 4/58 (6.9%) | 40/58 (69%) |
| Active Surveillance | — | 3/57 (5.3%) | 11/57 (19.3%) |
| Event | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| ErysipelasInfections and infestations | 0/58 | 1/57 |
| Urinary tract disorderRenal and urinary disorders | 0/58 | 1/57 |
| Pancreatic neoplasmGastrointestinal disorders | 0/58 | 1/57 |
| Atrial flutterCardiac disorders | 1/58 | 0/57 |
| FatigueVascular disorders | 1/58 | 0/57 |
| DizzinessVascular disorders | 1/58 | 0/57 |
| DeafnessEar and labyrinth disorders | 1/58 | 0/57 |
| Event | Leuprorelin 11.25 mg | Active Surveillance |
|---|---|---|
| Hot flushReproductive system and breast disorders | 17/58 | 0/57 |
| FlushingVascular disorders | 9/58 | 0/57 |
| Erectile dysfunctionPsychiatric disorders | 7/58 | 2/57 |
| Libido decreasedReproductive system and breast disorders | 6/58 | 0/57 |
| Hot flushVascular disorders | 6/58 | 0/57 |
| Back painMusculoskeletal and connective tissue disorders | 2/58 | 4/57 |
| FatigueGeneral disorders | 4/58 | 0/57 |
| DysuriaRenal and urinary disorders | 4/58 | 2/57 |
| HypertensionVascular disorders | 1/58 | 3/57 |
| BronchitisInfections and infestations | 3/58 | 2/57 |
Full Analysis Set included all participants with prostate cancer who signed informed consent and were randomised.
| Age, Continuous(years) | Leuprorelin 11.25 mg | Active Surveillance | Total |
|---|---|---|---|
| Mean | 66.22 ± 5.76 | 63.60 ± 5.56 | 64.92 ± 5.79 |
| Sex: Female, Male(Participants) | Leuprorelin 11.25 mg | Active Surveillance | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 58 | 57 | 115 |
| Region of Enrollment(Participants) | Leuprorelin 11.25 mg | Active Surveillance | Total |
|---|---|---|---|
| France | 58 | 57 | 115 |
| Height(centimeters (cm)) | Leuprorelin 11.25 mg | Active Surveillance | Total |
|---|---|---|---|
| Mean | 171.85 ± 6.55 | 173.69 ± 8.08 | 172.77 ± 7.38 |
Ran from Jun 2013 to primary completion in Nov 2016, 41 months.
Results were first posted in Apr 2019, 2 years 5 months after primary completion. A results delay was requested in Feb 2017.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 41 months is close to that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide